m10@T-MNVs

Stages

1. 1.
   Build IL-10 mRNA-loaded peptide-functionalized nanovesicles(library_build)

   This stage creates the vesicular carrier component that packages IL-10 mRNA and adds cardiac-targeting peptide functionality before magnetic assembly.

   Selection: Assembly of IL-10 mRNA-loaded T-NVs by fusing IL-10 mRNA lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and adding cardiac-targeting peptides

2. 2.
   Functionalize magnetic nanoparticles for injured-cardiac targeting(library_build)

   This stage equips magnetic nanoparticles to bind CD63-positive vesicle components and target damaged myocardial tissue through MLC3 recognition.

   Selection: Conjugation of azide-modified anti-CD63 and anti-MLC3 antibodies to magnetic nanoparticles via click chemistry

3. 3.
   Assemble dual-active magnetic nanovesicles(library_build)

   This stage produces the final composite carrier that integrates vesicle targeting and magnetic localization functions.

   Selection: Combination of m10@T-NVs with functionalized magnetic nanoparticles via CD63 interactions to form m10@T-MNVs

4. 4.
   Characterize assembled nanocarrier(functional_characterization)

   This stage verifies that the intended functionalization and assembly steps succeeded before biological testing.

   Selection: Confirmation of nanovesicle and magnetic nanoparticle functionalization

5. 5.
   Test magnetic targeting and delivery efficiency in injured cardiac settings(confirmatory_validation)

   This stage checks whether the assembled carrier actually localizes to injured cardiac targets and improves delivery before therapeutic interpretation.

   Selection: Accumulation in H2O2-induced injured cardiomyocytes and damaged cardiac regions under an external magnetic field

6. 6.
   Evaluate therapeutic efficacy in mouse myocardial infarction(in_vivo_validation)

   This stage validates whether targeted delivery translates into therapeutic benefit in myocardial infarction.

   Selection: Enhanced intramyocardial IL-10 mRNA expression and downstream anti-inflammatory and tissue-protective effects in a mouse MI model

Steps

1. 1.
   Encapsulate IL-10 mRNA in lipid nanoparticles

   Package the therapeutic mRNA cargo before fusion into nanovesicles.

   The abstract states that IL-10 mRNA was first encapsulated in lipid nanoparticles before those particles were fused with mesenchymal stem cell-derived nanovesicles.

2. 2.
   Fuse IL-10 mRNA lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and functionalize with cardiac-targeting peptidesengineered carrier intermediate

   Generate IL-10 mRNA-loaded T-NVs as the vesicular targeting component.

   This follows mRNA encapsulation because the loaded lipid nanoparticles are the material fused into nanovesicles to create m10@T-NVs.

3. 3.
   Conjugate azide-modified anti-CD63 and anti-MLC3 antibodies to magnetic nanoparticles via click chemistry

   Create magnetic nanoparticles that can both associate with CD63-positive vesicle material and target injured myocardium.

   The magnetic nanoparticles must be functionalized before they can be combined with m10@T-NVs to form the final magnetic nanovesicle construct.

4. 4.
   Combine m10@T-NVs with functionalized magnetic nanoparticles via CD63 interactions to form m10@T-MNVsfinal engineered carrier assembly

   Produce the dual-active magnetic nanocarrier used for targeting and therapy.

   This assembly depends on prior preparation of both the m10@T-NV intermediate and the antibody-functionalized magnetic nanoparticles.

5. 5.
   Characterize m10@T-MNVs to confirm nanovesicle and magnetic nanoparticle functionalizationengineered carrier under characterization

   Verify successful functionalization and assembly of the final carrier.

   Characterization is reported before biological performance claims and serves as confirmation that the intended construct was produced.

6. 6.
   Assess accumulation of m10@T-MNVs in injured cardiomyocytes and damaged cardiac regions under an external magnetic fieldcarrier under targeting evaluation

   Determine whether magnetic guidance improves localization and delivery efficiency in injured cardiac settings.

   This targeting test follows construct characterization and precedes in vivo therapeutic interpretation because the workflow aims to show that the carrier reaches injured tissue efficiently.

7. 7.
   Administer m10@T-MNVs in a mouse myocardial infarction model and measure intramyocardial IL-10 expression and downstream therapeutic effectstherapeutic delivery system

   Test whether targeted delivery of IL-10 mRNA produces anti-inflammatory and tissue-protective effects in vivo.

   This is the highest-fidelity validation stage because it tests whether the engineered targeting strategy translates into therapeutic benefit in an MI animal model.